Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In our experience, reaching a rapid drug substance material delivery to support toxicology studies is becoming a major milestone on the Phase I CMC clinical development path (Figure 1).

Drug Development 64

Drug Development Clinical Supply Production Protein Expression 64

BioPharma Drive: Drug Pricing

JUNE 9, 2025

Its new CEO has to figure out what’s next.

Clinical Trials 141

Clinical Trials Drugs Therapies Clinical Supply 141

BioPharma Drive: Drug Pricing

JUNE 9, 2025

Most Popular Biotech funding plummets as Trump policies unnerve investors: Jefferies Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO FDA to use new review tool on Sarepta’s gene therapy work FDA meeting gives window into gene therapy field’s angst Library resources Playbook First-Void Urine Testing: A Simpler Option (..)

Trials 130

Trials Clinical Supply Clinical Trials Therapies 130

BioPharma Drive: Drug Pricing

JUNE 5, 2025

Bloomberg 23andMe’s DNA Data Gets Boosted $305 Million Bid in New Auction View all Events 17 JUN Webinar | 10:30 a.m. Its new CEO has to figure out what’s next.

FDA 130

FDA Therapies Clinical Supply Licensing 130

Drug Target Review

MAY 27, 2025

I sequenced the complementary DNA (cDNA) encoding RAS GTPase Activating Protein, a protein known that regulates cell growth, differentiation and survival of cells; mutations in these proteins are linked to cancer. My proudest achievement is my leadership journey building legacy organisations, processes and tools in clinical operations.

Clinical Trials 52

Clinical Trials Molecular Biology Trials Clinical Supply 52